{"id":"meropenem-active-comparator","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Injection site reaction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This binding results in the disruption of the bacterial cell wall, ultimately leading to cell lysis and death. Meropenem has a broad spectrum of activity against both Gram-positive and Gram-negative bacteria.","oneSentence":"Meropenem is a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:56.789Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Complicated intra-abdominal infections"},{"name":"Complicated urinary tract infections"},{"name":"Nosocomial pneumonia"}]},"trialDetails":[{"nctId":"NCT07484633","phase":"PHASE4","title":"A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients.","status":"NOT_YET_RECRUITING","sponsor":"Semmelweis University","startDate":"2026-04","conditions":"Infection, Sepsis, NICU","enrollment":110},{"nctId":"NCT04692181","phase":"PHASE1, PHASE2","title":"SYN-004 Safety and Tolerability in Allo-HCT Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Theriva Biologics, Inc.","startDate":"2021-02-15","conditions":"Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant, Prevention of CDI in Adult Patients Being Treated With IV Beta-lactam Antibiotics","enrollment":36},{"nctId":"NCT06080698","phase":"NA","title":"Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2024-02-22","conditions":"Gram-negative Bacteremia","enrollment":1030},{"nctId":"NCT07327619","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-01-22","conditions":"Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia","enrollment":420},{"nctId":"NCT06537609","phase":"NA","title":"A Platform Trial for Gram Negative Bloodstream Infections","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2024-04-24","conditions":"Gram-negative Bacteremia","enrollment":2500},{"nctId":"NCT04478721","phase":"PHASE3","title":"Temocillin vs Meropenem for the Targeted Treatment of Bacteraemia Resistant to Third Gen Cephalosporins","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2020-12-15","conditions":"Bacteremia","enrollment":334},{"nctId":"NCT06672276","phase":"PHASE1","title":"To Evaluate the Pharmacokinetics and Safety of TQD3606 for Injection in Subjects With Renal Insufficiency","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-11-20","conditions":"Resistant to Gram-positive, Gram-negative and Anaerobic Bacteria","enrollment":32},{"nctId":"NCT07326540","phase":"PHASE3","title":"Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex","status":"NOT_YET_RECRUITING","sponsor":"BioVersys SAS","startDate":"2026-03-20","conditions":"Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Associated Bacterial Pneumonia (VABP), Colistin Resistanrt ABC","enrollment":248},{"nctId":"NCT07318584","phase":"PHASE2","title":"Cefotetan Therapy for Escherichia Coli Infections","status":"NOT_YET_RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2026-03","conditions":"E Coli Infection, ESBL Producing E.Coli","enrollment":84},{"nctId":"NCT07314281","phase":"PHASE4","title":"Meropenem vs Azithromycin Efficacy in Case XDR Enteric Fever","status":"RECRUITING","sponsor":"Indus Hospital and Health Network","startDate":"2025-04-22","conditions":"Enteric Fever","enrollment":40},{"nctId":"NCT07236944","phase":"PHASE4","title":"Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2025-12","conditions":"Febrile Urinary Tract Infection","enrollment":560},{"nctId":"NCT03543436","phase":"PHASE3","title":"Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-01-04","conditions":"Urinary Tract Infections","enrollment":29},{"nctId":"NCT07096310","phase":"PHASE1, PHASE2","title":"Comparison Between Carbapenems and Noncarbapenem Beta-lactam Antibiotics in Septic Burn Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ain Shams University","startDate":"2024-01-01","conditions":"Sepsis","enrollment":400},{"nctId":"NCT04979806","phase":"PHASE3","title":"Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)","status":"COMPLETED","sponsor":"Wockhardt","startDate":"2022-08-28","conditions":"Complicated Urinary Tract Infection, Acute Pyelonephritis","enrollment":530},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT07122596","phase":"PHASE4","title":"EFFICACY OF PROLONGED INFUSION MEROPENEM IN CRITICALLY ILL PAEDIATRIC INTENSIVE CARE PATIENTS","status":"COMPLETED","sponsor":"Pakistan Navy Station Shifa Hospital","startDate":"2024-04-01","conditions":"Sepsis, Bacterial Infection","enrollment":150},{"nctId":"NCT03452839","phase":"PHASE4","title":"Bolus Versus Continuous Infusion of Meropenem","status":"COMPLETED","sponsor":"Università Vita-Salute San Raffaele","startDate":"2018-06-05","conditions":"Antibiotic Resistant Infection, Critical Illness","enrollment":607},{"nctId":"NCT03671967","phase":"PHASE4","title":"PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)","status":"RECRUITING","sponsor":"Rambam Health Care Campus","startDate":"2019-05-01","conditions":"Beta Lactam Resistant Bacterial Infection, Enterobacteriaceae Infections, Bacteremia","enrollment":1084},{"nctId":"NCT05922124","phase":"PHASE4","title":"Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii","status":"RECRUITING","sponsor":"Rambam Health Care Campus","startDate":"2024-09-01","conditions":"Carbapenem Resistant Bacterial Infection, Acinetobacter Bacteremia, Acinetobacter Pneumonia","enrollment":734},{"nctId":"NCT07089186","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-04-12","conditions":"Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP), Complicated Intra-abdominal Infection (cIAI)","enrollment":80},{"nctId":"NCT05355350","phase":"PHASE4","title":"PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections","status":"WITHDRAWN","sponsor":"Rambam Health Care Campus","startDate":"2022-07-01","conditions":"Beta Lactam Resistant Bacterial Infection, Enterobacteriaceae Infections, Bacteremia","enrollment":""},{"nctId":"NCT06184659","phase":"PHASE4","title":"Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis","status":"RECRUITING","sponsor":"Scandinavian Critical Care Trials Group","startDate":"2025-06-26","conditions":"Sepsis, Septic Shock","enrollment":5800},{"nctId":"NCT06168734","phase":"PHASE3","title":"Cefepime-taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP","status":"WITHDRAWN","sponsor":"Venatorx Pharmaceuticals, Inc.","startDate":"2025-06","conditions":"Ventilator-associated Pneumonia, Hospital-acquired Pneumonia","enrollment":""},{"nctId":"NCT03840148","phase":"PHASE3","title":"Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections","status":"COMPLETED","sponsor":"Venatorx Pharmaceuticals, Inc.","startDate":"2019-08-07","conditions":"Urinary Tract Infections, Acute Pyelonephritis","enrollment":661},{"nctId":"NCT07004049","phase":"PHASE4","title":"Optimising TREATment for Severe Gram-Negative Bacterial Infections","status":"RECRUITING","sponsor":"National University of Singapore","startDate":"2025-04-21","conditions":"Bloodstream Infection, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia","enrollment":600},{"nctId":"NCT06051513","phase":"NA","title":"Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection","status":"RECRUITING","sponsor":"Southeast University, China","startDate":"2023-11-27","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection","enrollment":404},{"nctId":"NCT06342115","phase":"PHASE4","title":"Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens","status":"RECRUITING","sponsor":"Beneficência Portuguesa de São Paulo","startDate":"2025-03-26","conditions":"Febrile Neutropenia","enrollment":176},{"nctId":"NCT05578586","phase":"NA","title":"A Pilot Study for Optimizing Meropenem Administration in the ICU","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2021-12-14","conditions":"Drug Effect","enrollment":50},{"nctId":"NCT06841731","phase":"PHASE2","title":"A Trial of HRS-8427 in the Treatment of Adults With Bacterial Pneumonia","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-04-03","conditions":"Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP)","enrollment":100},{"nctId":"NCT06929702","phase":"PHASE4","title":"Precision Dosing of Beta-lactam Antibiotics in Critically Ill Children","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2025-04-22","conditions":"Amoxicillin-clavulanate, Piperacillin-tazobactam, Meropenem","enrollment":58},{"nctId":"NCT06818565","phase":"NA","title":"Comparison of Efficacy and Safety of Ceftazidime Avibactam Versus Extended Infusions of High Dose Meropenem in Patients of ACLF With Nosocomial Infections.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2025-02-10","conditions":"Acute-On-Chronic Liver Failure","enrollment":150},{"nctId":"NCT02820987","phase":"PHASE3","title":"PK/PD of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2016-09-27","conditions":"Septic Shock","enrollment":119},{"nctId":"NCT06739382","phase":"PHASE3","title":"Management of Ventilation Acquired Pneumonia Caused by Pseudomonas and Acinetobacter Organisms in a Pediatric Center","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2021-01-01","conditions":"Ventilation Acquired Pneumonia","enrollment":64},{"nctId":"NCT03329092","phase":"PHASE3","title":"A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-04-05","conditions":"Complicated Intra-abdominal Infection, Hosptial Acquired Pneumonia, Ventilator Associated Pneumonia","enrollment":422},{"nctId":"NCT03891433","phase":"PHASE4","title":"Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae","status":"SUSPENDED","sponsor":"Universidad del Norte","startDate":"2019-04-01","conditions":"Urinary Tract Infections, Enterobacteriaceae Infections, Infection Due to ESBL Bacteria","enrollment":198},{"nctId":"NCT04983901","phase":"PHASE2","title":"PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-14","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm","enrollment":100},{"nctId":"NCT04882085","phase":"PHASE4","title":"Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-08-26","conditions":"Urinary Tract Infection, Acute Pyelonephritis, Hospital Acquired Pneumonia","enrollment":60},{"nctId":"NCT05925309","phase":"NA","title":"Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2023-07-01","conditions":"Biliary Atresia, Cholangitis, Anti-Bacterial Agents","enrollment":356},{"nctId":"NCT06633718","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2024-10-31","conditions":"Intra-abdominal Infections","enrollment":786},{"nctId":"NCT05893147","phase":"NA","title":"BALANCE+ Vanguard Phase","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2023-08-26","conditions":"Gram-negative Bacteremia","enrollment":174},{"nctId":"NCT05784844","phase":"PHASE4","title":"Antimicrobial Revision in Persistent Febrile Neutropenia","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2024-08","conditions":"Febrile Neutropenia","enrollment":""},{"nctId":"NCT05786495","phase":"NA","title":"Short Antibiotic Treatment in High Risk Febrile Neutropenia","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-10-01","conditions":"Febrile Neutropenia","enrollment":80},{"nctId":"NCT06293677","phase":"PHASE4","title":"Adjustment of Antibiotic Dosage in Pediatric Oncology Patients With Febrile Neutropenia and Augmented Renal Clearance","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2024-03-01","conditions":"Febrile Neutropenia","enrollment":30},{"nctId":"NCT05926063","phase":"PHASE4","title":"Stopping Antibiotics After 3 Days for the Treatment of High-risk FEbrile Neutropenia","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2024-02-26","conditions":"Neutropenia, Febrile","enrollment":410},{"nctId":"NCT05105035","phase":"PHASE2","title":"Oral ARV-1801 Given in Combination With Intravenous Ceftazidime or Meropenem for Treatment of Melioidosis in Hospitalized Patients","status":"COMPLETED","sponsor":"Arrevus Inc.","startDate":"2022-06-14","conditions":"Melioidosis","enrollment":125},{"nctId":"NCT06198764","phase":"PHASE3","title":"A Clinical Trial for the Treatment of Carbapenem Resistant Gram-negative Bacterial Infection With Colistimethate Sodium for Injection","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-07-06","conditions":"Mental Health Issue","enrollment":80},{"nctId":"NCT05102162","phase":"PHASE4","title":"BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia","status":"TERMINATED","sponsor":"University of Florida","startDate":"2021-12-17","conditions":"Pneumonia","enrollment":35},{"nctId":"NCT06072222","phase":"PHASE1, PHASE2","title":"Effect of Bronchoscopy on the Outcome of Patients With Severe Sepsis With ARDS and Complicated by VAP From Prolonged Ventilation","status":"COMPLETED","sponsor":"King Abdul Aziz Specialist Hospital","startDate":"2020-07-02","conditions":"ARDS, Septic Shock","enrollment":200},{"nctId":"NCT06072248","phase":"PHASE1, PHASE2","title":"Effect of Bronchoscopy on the Outcome of Patients With Severe Sepsis With ARDS and Complicated by VAP From Prolonged Ventilation","status":"COMPLETED","sponsor":"King Abdul Aziz Specialist Hospital","startDate":"2020-07-02","conditions":"ARDS, Septic Shock","enrollment":200},{"nctId":"NCT03237182","phase":"PHASE4","title":"The Individualized M(X) Drug-resistant TB Treatment Strategy Study","status":"TERMINATED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2017-06-14","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":205},{"nctId":"NCT05293132","phase":"PHASE2, PHASE3","title":"Effect of Montelukast Versus Co Enzyme in Sepsis","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-02-01","conditions":"Sepsis","enrollment":90},{"nctId":"NCT03630081","phase":"PHASE3","title":"Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)","status":"UNKNOWN","sponsor":"Wockhardt","startDate":"2024-01","conditions":"Complicated Urinary Tract Infection, Acute Pyelonephritis","enrollment":1004},{"nctId":"NCT05896930","phase":"PHASE2","title":"Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"TASK Applied Science","startDate":"2017-11-09","conditions":"Pulmonary Tuberculosis","enrollment":134},{"nctId":"NCT02437045","phase":"PHASE4","title":"Trial of Meropenem Versus Piperacillin-Tazobactam on Mortality and Clinial Response","status":"COMPLETED","sponsor":"The University of Queensland","startDate":"2015-04","conditions":"Bloodstream Infections","enrollment":100},{"nctId":"NCT05850871","phase":"NA","title":"Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2023-01-06","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection","enrollment":427},{"nctId":"NCT03217136","phase":"PHASE2","title":"MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-04-03","conditions":"Complicated Intra-Abdominal Infection","enrollment":94},{"nctId":"NCT03230838","phase":"PHASE2","title":"MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-04-26","conditions":"Complicated Urinary Tract Infection, Pyelonephritis","enrollment":134},{"nctId":"NCT05565222","phase":"PHASE3","title":"Piperacillin-tazobactam and Temocillin as Carbapenem-alternatives for the Treatment of Severe Infections Due to Extended-spectrum Beta-lactamase-Producing Gram-negative Enterobacteriaceae in the Intensive Care Unit","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-03-11","conditions":"Sepsis, Septic Shock","enrollment":600},{"nctId":"NCT05204368","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)","status":"UNKNOWN","sponsor":"Evopoint Biosciences Inc.","startDate":"2023-03-30","conditions":"Complicated Urinary Tract Infection Including Acute Pyelonephritis","enrollment":780},{"nctId":"NCT03830333","phase":"PHASE3","title":"Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-03-20","conditions":"Complicated Intra-abdominal Infections","enrollment":268},{"nctId":"NCT05393505","phase":"PHASE4","title":"Fast-track Blood Test for Suspected Fever by Deficiency of a Kind of White Blood Cells As Main Defense Against Infection","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2022-10-24","conditions":"Neutropenic Fever","enrollment":344},{"nctId":"NCT01597973","phase":"PHASE3","title":"Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME)","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2012-10-06","conditions":"Pneumonia, Blood Stream Infection","enrollment":467},{"nctId":"NCT04553367","phase":"PHASE1, PHASE2","title":"Effect of Bronchoscopy on the Outcome of Patients With Severe Sepsis With ARDS and Complicated by VAP From Prolonged Ventilation","status":"COMPLETED","sponsor":"King Abdul Aziz Specialist Hospital","startDate":"2020-07-02","conditions":"ARDS, Septic Shock","enrollment":200},{"nctId":"NCT05392634","phase":"PHASE3","title":"Multicentral Preventive Antibiotics With Cystectomy Within Enhanced Recovery After Surgery","status":"UNKNOWN","sponsor":"N.N. Petrov National Medical Research Center of Oncology","startDate":"2022-02-02","conditions":"Bladder Cancer","enrollment":98},{"nctId":"NCT04238390","phase":"PHASE3","title":"Ceftolozane-tazobactam Versus Meropenem for ESBL and AmpC-producing Enterobacterales Bloodstream Infection","status":"WITHDRAWN","sponsor":"The University of Queensland","startDate":"2022-01","conditions":"Bacteremia Caused by Gram-Negative Bacteria","enrollment":""},{"nctId":"NCT05340530","phase":"PHASE1","title":"To Evaluate the Pharmacokinetic Effects of TQD3606 for Injection in Healthy Adult Subjects","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-04","conditions":"Infections","enrollment":56},{"nctId":"NCT04555798","phase":"PHASE1, PHASE2","title":"Effect of Arterio-venous ECMO on Severe Sepsis and ARDS","status":"COMPLETED","sponsor":"Mohamed Gaber Allam","startDate":"2022-02-01","conditions":"Patients With Respiratory Failure and Shocked","enrollment":100},{"nctId":"NCT04370145","phase":"PHASE4","title":"Antibiotics Treatment of Cholangitis Post-Kasai Portoenterostomy","status":"COMPLETED","sponsor":"Tongji Hospital","startDate":"2021-05-01","conditions":"Cholangitis, Secondary Biliary, Treatment Compliance, Antibodies Drug Specific","enrollment":160},{"nctId":"NCT03485950","phase":"PHASE2","title":"Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-05-16","conditions":"Other Infectious Diseases","enrollment":100},{"nctId":"NCT04629378","phase":"PHASE2","title":"Evaluating the EBA of Meropenem With Amoxicillin/Clavulanate and Pyrazinamide or Bedaquiline in Adults With PTB","status":"COMPLETED","sponsor":"TASK Applied Science","startDate":"2020-08-17","conditions":"Tuberculosis","enrollment":22},{"nctId":"NCT02784704","phase":"PHASE3","title":"Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections","status":"COMPLETED","sponsor":"Tetraphase Pharmaceuticals, Inc","startDate":"2016-10-13","conditions":"Complicated Intra-abdominal Infections, Complicated Appendicitis","enrollment":500},{"nctId":"NCT05060419","phase":"PHASE2","title":"Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2021-10-08","conditions":"Complicated Urinary Tract Infection, Acute Pyelonephritis","enrollment":150},{"nctId":"NCT03019965","phase":"NA","title":"Efficacy of Betalactam Antibiotics in Prolonged Infusion Compared to Intermittent in Pediatric Patients With Sepsis","status":"COMPLETED","sponsor":"Coordinación de Investigación en Salud, Mexico","startDate":"2017-02-01","conditions":"Sepsis","enrollment":426},{"nctId":"NCT04154722","phase":"PHASE4","title":"Comparison of Two Drugs Regimen in Treatment of Complicated Typhoid Fever in Children","status":"COMPLETED","sponsor":"Ziauddin University","startDate":"2019-06-20","conditions":"Typhoid Fever","enrollment":126},{"nctId":"NCT04879030","phase":"PHASE2, PHASE3","title":"Combination Antibiotic Therapy Compared to Monotherapy in the Treatment of Acute COPD","status":"COMPLETED","sponsor":"Haiphong University of Medicine and Pharmacy","startDate":"2020-01-01","conditions":"COPD Exacerbation Acute","enrollment":170},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT04030741","phase":"PHASE2, PHASE3","title":"Non-operative Treatment of Acute Non-perforated Appendicitis","status":"COMPLETED","sponsor":"King Edward Medical University","startDate":"2018-09-01","conditions":"Acute Appendicitis","enrollment":180},{"nctId":"NCT04233996","phase":"PHASE4","title":"Efficacy of Extended Infusion of β-lactam Antibiotics for the Treatment of Febrile Neutropenia in Hematologic Patients","status":"UNKNOWN","sponsor":"Hospital Universitari de Bellvitge","startDate":"2019-06-05","conditions":"Febrile Neutropenia","enrollment":150},{"nctId":"NCT03032380","phase":"PHASE3","title":"Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens","status":"COMPLETED","sponsor":"Shionogi","startDate":"2017-10-24","conditions":"Healthcare-associated Pneumonia (HCAP), Hospital Acquired Pneumonia (HAP), Ventilator Associated Pneumonia (VAP)","enrollment":300},{"nctId":"NCT03717350","phase":"PHASE2, PHASE3","title":"suPAR to Guide Antibiotics in Emergency Department","status":"UNKNOWN","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2018-10-27","conditions":"Sepsis","enrollment":220},{"nctId":"NCT04489459","phase":"PHASE4","title":"Comparative Clinical Study Between Colistin-Tigecycline Combined Therapy Versus Colistin-Meropenem Combined Therapy in Treatment of Blood Stream Infections With Multidrug-Resistant Klebsiella Pneumoniae","status":"UNKNOWN","sponsor":"Al-Azhar University","startDate":"2019-09-21","conditions":"Treatment of Blood Stream Infections Due to Multidrug-Resistant Klebsiella Pneumoniae","enrollment":60},{"nctId":"NCT02795949","phase":"PHASE3","title":"Study on Reduced Antibiotic Treatment vs Broad Spectrum Betalactam in Patients With Bacteremia by Enterobacteriaceae","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2016-10","conditions":"Enterobacteriaceae Infections","enrollment":344},{"nctId":"NCT02070757","phase":"PHASE3","title":"Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2014-09-02","conditions":"Healthcare-Associated Pneumonia, Ventilator-Associated Pneumonia, Lung Diseases","enrollment":726},{"nctId":"NCT02047773","phase":"PHASE4","title":"Bacterial Load Guided Therapy for Severe Bronchiectasis Exacerbations","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2014-01","conditions":"Bronchiectasis","enrollment":90},{"nctId":"NCT03915236","phase":"NA","title":"Approach for Optimizing Meropenem Therapy in Intubated and Mechanically-Ventilated, Adult Patients With Severe Gram-Negative Lower Respiratory Tract Infection","status":"TERMINATED","sponsor":"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","startDate":"2019-02-18","conditions":"Lower Respiratory Tract Infection","enrollment":7},{"nctId":"NCT02894684","phase":"PHASE4","title":"Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis","status":"COMPLETED","sponsor":"Liverpool Heart and Chest Hospital NHS Foundation Trust","startDate":"2017-01","conditions":"Cystic Fibrosis, Infection, Pseudomonas","enrollment":16},{"nctId":"NCT03477422","phase":"PHASE3","title":"CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) Compared to Meropenem in Complicated Urinary Tract Infections (cUTIs) Caused by ESBL Producing Gram Negative Bacteria","status":"COMPLETED","sponsor":"Venus Remedies Limited","startDate":"2014-01-11","conditions":"Urinary Tract Infection Complicated, Acute Pyelonephritis","enrollment":230},{"nctId":"NCT03409679","phase":"PHASE3","title":"Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa","status":"TERMINATED","sponsor":"Polyphor Ltd.","startDate":"2018-03-23","conditions":"Pneumonia","enrollment":41},{"nctId":"NCT03582007","phase":"PHASE3","title":"Pivotal Study in Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas","status":"TERMINATED","sponsor":"Polyphor Ltd.","startDate":"2018-10-22","conditions":"Pneumonia","enrollment":2},{"nctId":"NCT02142751","phase":"PHASE3","title":"Fosfomycin Versus Meropenem or Ceftriaxone in Bacteriemic Infections Caused by Multidrug Resistance in E.Coli","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2014-07","conditions":"Infection Due to ESBL Escherichia Coli","enrollment":161},{"nctId":"NCT03344627","phase":"NA","title":"Clinical Outcome Study of High-dose Meropenem in Sepsis and Septic Shock Patients","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2017-11-27","conditions":"Sepsis, Septic Shock, Critical Illness","enrollment":76},{"nctId":"NCT02168946","phase":"PHASE3","title":"Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults","status":"COMPLETED","sponsor":"Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)","startDate":"2014-07","conditions":"Urinary Tract Infection Complicated, Acute Pyelonephritis, Hospital Acquired Bacterial Pneumonia","enrollment":77},{"nctId":"NCT03006679","phase":"PHASE3","title":"A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia","status":"WITHDRAWN","sponsor":"Melinta Therapeutics, Inc.","startDate":"2018-08","conditions":"Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia, Hospital-Acquired Pneumonia","enrollment":""},{"nctId":"NCT03564158","phase":"PHASE1","title":"Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy Volunteers","status":"COMPLETED","sponsor":"Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)","startDate":"2018-05-01","conditions":"Healthy","enrollment":53},{"nctId":"NCT01445678","phase":"PHASE3","title":"Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2011-12-23","conditions":"Complicated Intra-abdominal Infection","enrollment":494},{"nctId":"NCT01147640","phase":"PHASE2","title":"Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2010-06-25","conditions":"Complicated Intra-abdominal Infection","enrollment":122},{"nctId":"NCT01970371","phase":"PHASE3","title":"A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)","status":"COMPLETED","sponsor":"Achaogen, Inc.","startDate":"2014-09-16","conditions":"Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE, Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE","enrollment":69},{"nctId":"NCT02349841","phase":"PHASE2","title":"Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"TASK Applied Science","startDate":"2014-09","conditions":"Pulmonary Tuberculosis","enrollment":46},{"nctId":"NCT02486627","phase":"PHASE3","title":"A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP)","status":"COMPLETED","sponsor":"Achaogen, Inc.","startDate":"2016-01-11","conditions":"Complicated Urinary Tract Infection, Acute Pyelonephritis","enrollment":609},{"nctId":"NCT03622450","phase":"PHASE2, PHASE3","title":"The Effect of Colistin Inhalation on Ventilator Associated Pneumonia","status":"COMPLETED","sponsor":"Nourhan Hassan Osama Thuraya Mohamed","startDate":"2016-01-02","conditions":"Ventilator Associated Pneumonia","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"meropenem (active comparator)","genericName":"meropenem (active comparator)","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Meropenem is a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Complicated intra-abdominal infections, Complicated urinary tract infections, Nosocomial pneumonia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}